Tag: biologicals
IPL Biologicals becomes first Non-European & Non-American company to win Prestigious...
The Bernard Blum Awards, among the highest recognitions in the biological industry, celebrate products that exemplify exceptional innovation, efficacy, and environmental sustainability
Shilpa Biologicals opens bioconjugation manufacturing site at Dharwad
New bioconjugation services to complete the CDMO’s end-to-end capabilities across payload, linker, and MAb
IPL Biologicals expands its product portfolio, launches 6 new products under...
Each product has been developed with a focus on soil health, nutrient availability, and microbial efficacy across varied agro-climatic zones
Biocon Biologics partners Sandoz Australia for sale of biosimilars, Trastuzumab &...
The agreement is effective from January 1, 2024 and commercialization commenced on February 1, 2024
IPL Biologicals announces MOU with Gujarat govt for developing agro biologicals...
Investment of 400 Crores in Gujarat to propel sustainable agriculture and environmental health
Indian Immunologicals celebrates 25 years of Human Biologicals Institute
The company also launched live attenuated MR vaccine in an exclusive partnership with Polyvac Institute, Vietnam
Cytiva aims to double its manufacturing capacity in India, launches new...
According to Cytiva’s 2023 Global Biopharma Resilience Index, the manufacturing of biologics in India is likely to increase over the next three years
India’s biosimilars industry staring at plethora of opportunities
Between now and 2030, biologic products worth US $170 billion will lose patent protection globally, writes Dr Cyrus Karkaria, President – Biotechnology, Lupin Limited
Inflation law drives biologic drugs to outpace small molecules in venture...
According to GlobalData’s Pharma Intelligence Center Deals database, the US biotechs saw 48% or $1.1 billion more in innovator drug venture financing, reaching a total deal value of $3.2 billion in 2023
Biocon revenue up 59% at Rs 3,929 crore in Q4FY23
The company's revenue in biosimilars is up 114%; research services up 31% and EBITDA at Rs 1,152 crore up 75%